HCV infection-associated hepatocellular carcinoma in humanized mice. by Wang, Zhao et al.
Himmelfarb Health Sciences Library, The George Washington University
Health Sciences Research Commons
Biochemistry and Molecular Medicine Faculty
Publications Biochemistry and Molecular Medicine
1-2015
HCV infection-associated hepatocellular








Follow this and additional works at: http://hsrc.himmelfarb.gwu.edu/smhs_biochem_facpubs
Part of the Biochemistry, Biophysics, and Structural Biology Commons
This Journal Article is brought to you for free and open access by the Biochemistry and Molecular Medicine at Health Sciences Research Commons. It
has been accepted for inclusion in Biochemistry and Molecular Medicine Faculty Publications by an authorized administrator of Health Sciences
Research Commons. For more information, please contact hsrc@gwu.edu.
Recommended Citation
Wang, Z., Wu, N., Tesfaye, A., Feinstone, S., & Kumar, A. (2015). HCV infection-associated hepatocellular carcinoma in humanized
mice. Infectious Agents and Cancer, 10, 24.
RESEARCH ARTICLE Open Access
HCV infection-associated hepatocellular
carcinoma in humanized mice
Zhao Wang1†, Ningbin Wu1†, Abeba Tesfaye2, Stephen Feinstone1,2 and Ajit Kumar1,3*
Abstract
Background and Aims: Hepatitis C virus (HCV) infection is a major risk factor for chronic hepatitis, cirrhosis and
hepatocellular carcinoma (HCC). Our aim is to explore molecular changes that underlie HCV infection-associated
HCC in a humanized mouse model, in order to identify markers of HCC progression.
Methods: Liver proteins from human hepatocyte-engrafted and HCV-infected MUP-uPA/SCID/Bg mice were
compared with either uninfected controls or HCV-infected but HCC-negative mice by Western blotting. MicroRNA
markers of HCC positive or uninfected mouse liver were analyzed by RT-PCR.
Results: We describe the depletion of tumor suppressor proteins and induction of oncoproteins and oncogenic
microRNAs (oncomiRs) in HCV-infection associated HCC. Similar depletion of PTEN protein in both HCC-positive
and HCV-infected but HCC-negative liver suggests that PTEN depletion is an early, precancerous marker of HCC.
By contrast, induction of oncoprotein cMyc, oncomiRs (miR21, miR221 and miR141) and inflammatory response
proteins correspond to HCC progression.
Conclusions: While the loss of PTEN is important for the initiation of HCV infection-associated HCC, PTEN depletion
by itself is insufficient for tumor progression. Liver tumor progression requires induction of oncoproteins and
oncomiRs. Overall, human hepatocyte-engrafted (MUP-uPA/SCID/Bg) mice provide a suitable small animal model
for studying the effects of oncogenic changes that promote HCV infection associated HCC.
Keywords: HCV Infection-associated HCC
Introduction
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer worldwide; its incidence is increasing because
of the prevalence of chronic hepatitis C and B viral infec-
tions [1, 2]. The mechanism of HCV infection-associated
HCC, however, is not well understood. To gain an under-
standing of the oncogenic changes that underlie HCC pro-
gression, we contrasted the expression levels of oncogenic
proteins and microRNAs in liver tissues of a humanized
mouse model of HCV infection-associated HCC [3].
Earlier reports of molecular markers of liver cancer in
a mouse model were examined by ex vivo manipulation
of progenitor cells followed by their transplantation into
recipient mice [4–6]. While these studies initiated with
progenitor cells harboring cancer-predisposing lesions
identified valuable markers of liver cancer, they do not
model HCV infection-associated HCC.
Unlike the expression of uPA transgene under albumin
promoter (Alb-uPA) as originally described [7], MUP-
uPA/SCID/Bg mice studied in this report, provide a long
window of time (up to 12 months) for hepatocyte en-
graftment and efficient infection with HBV or HCV [3].
We observed primary liver cancers within the engrafted
human liver in about 25 % HCV infected mice, at four
to six months post-infection.
To identify molecular markers of HCV infection-
associated HCC, we compared expression levels of onco-
proteins and tumor suppressor proteins from liver tissues
of HCV-infected HCC with the HCV-infected but HCC-
negative mice. Results suggest that loss of PTEN tumor
suppressor protein is an early indicator of HCV infection-
associated HCC. By contrast, induction of c-Myc and
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inflammatory response molecules, correlate with HCC
progression.
Micro-RNAs have been studied as independent markers
of oncogenic progression [8]. In comparison with miRNAs
reported from liver cancer of unspecified origin, our
analysis suggests that induction of oncomiRs (miR-21,
miR-221 and miR-141) and tumor suppressor miR-26a
constitute signature miRNA markers of HCV infection-
associated HCC. Overall, the results indicate that human
hepatocyte engrafted MUP-uPA/SCID/Bg mice are a suit-
able small animal model for studying HCV-infected HCC
and the role of tumor-promoting factors in liver cancer.
Methods
Scheme for generation of humanized mice
Procedures for human hepatocyte engraftment and HCV
infection of immune compromised (MUP-uPA/SCID/Bg)
mice were described earlier [3]. Eleven of 42 HCV-
infected mice developed tumors four to six months post-
infection; the controls, 21 mice that were engrafted but
not infected, or 23 mice that were not engrafted, did not
develop tumors after being followed for the same
period. Histologic changes similar to human hepatocel-
lular carcinoma were observed within enografted hu-
man liver of HCV-infected mice; as well, the tumors
stained for human albumin and human glypican-3
(Tesfaye et al, unpublished).
Protein extraction, subcellular fractionation and
immunoblotting
Liver tissues used for Western blot analysis were from
human hepatocyte-engrafted MUP-uPA/SCID/Bg unin-
fected control, or HCV-infected but HCC-negative or
HCV infection-induced liver tumors (HCC positive) mice.
Liver samples were stored at -80 °C until analysis.
Liver tissues were lysed with RIPA buffer supplemented
with protease inhibitor cocktail (Roche) as described [9].
Cell fractionation kit (Thermo Pierce) was used for the
fractionation of nuclear and cytoplasmic proteins. Briefly,
200 μL Cytoplasmic Extraction Reagent (CER I) was used
to homogenize liver tissues followed by the addition of
11 μL Cytoplasmic Extraction Reagent II (CER II) to pre-
cipitate the nuclear fraction. 100 μL of Nuclear Extraction
Reagent (NER) was used to extract the nuclear fraction.
Equal amounts (10 μg) of protein fractions were analyzed
on 10 % precast Mini-PROTEIN gel (BIO-RAD). Proteins
were transferred to PVDF membrane, blocked with 5 %
non-fat milk and probed with antibodies (Abcam) as indi-
cated. HRP conjugated anti-rabbit or anti-goat antibodies
(Abcam; SuperSignal West Dura Chemiluminescent Sub-
strate) were visualized with BIO-RAD ChemiDoc™ XRS+
System. Estimates of relative protein levels were based on
β-actin as internal (loading) control. Western blot images
were quantified (by Image Lab™ Software developed by
BIO-RA) as described earlier [9–11]. Statistical analysis
was based on paired t-test for each subgroup compared
with the reference (loading controls). Data shown is SE of
the mean (SEM). Statistical significance is set to *p < 0.05.
Real-time quantitative PCR of RNA samples from chimeric
mouse liver
1ug of total RNA was added to QuantiMir RT Kit Small
RNA Quantification System (System Biosciences) follow-
ing the manufacturer’s protocol. The reverse-transcribed
product was then diluted 40 fold. Real time quantitative
PCR was performed with iTaq SYBR Green Supermix
with Rox (Bio-Rad) on ABI 7300 PCR system. Primers
used for detecting hsa-miR-141, hsa-miR-23a, hsa-miR-
122, hsa-miR-181, hsa-miR-21, hsa-miR-221, hsa-miR-26a
and hsa-miR-16 respectively were as follows: 5’-TAACA
CTGTC TGGTA AAGAT GG-3’, 5’-ATCAC ATTGC
CAGGG ATTTC C-3’, 5’-TGGAG TGTGA CAATG
GTGTT TG-3’, 5’-AACAT TCAAC GCTGT CGGTG
AGT-3’, 5’-TAGCT TATCA GACTG ATGTT GA-3’, 5’-
AGCTA CATTG TCTGC TGGGT TTC-3’, 5’-TTCAA
GTAAT CCAGG ATAGG CT-3’ and 5’-TAGCA GCACG
TAAATATTGG CG-3’
Statistical analysis: All quantitative real-time PCR and
densitometry data were analyzed using Microsoft Excel
2010, using miR-16 (which does not change following
HCV infection) for normalization.
Results
Inactivation of tumor suppressor and amplification of
oncogene
Loss of tumor suppressor proteins and induction of
oncogenic proteins are the initiating events that promote
deregulation of molecular pathways underlying the de-
velopment of hepatocellular carcinoma [12, 13]. We in-
vestigated whether HCV infection associated HCC is
characterized by the loss of tumor suppressor proteins.
Of particular interest is the deregulation of PTEN tumor
suppressor due to its critical role in hepatocellular carcin-
oma [14–16]. Viral role in PTEN depletion was suggested
in an earlier report which showed that HCV-derived small
non-coding RNA restricted nuclear translocation of PTEN
protein by down-regulating Transportin 2 expression in
HCV-infected human hepatocytes [9]. Here we investi-
gated whether the loss of PTEN defines HCC progression
in a humanized mouse model of HCV infection.
Immunoblots of PTEN protein from liver tumors (T)
of thirteen hepatocyte-engrafted and HCV-infected MUP-
uPA/SCID/bg mice and twelve control (C) mice that were
engrafted with human hepatocytes but not infected with
HCV are shown Fig. 1. We also examined liver tissues
from seven MUP-uPA/SCID/bg mice that were engrafted
with human hepatocytes and infected with HCV but
remained HCC-negative (N). We observed a consistent
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decline of both nuclear (Fig. 1a and c) and cytoplasmic
(Fig. 1b) PTEN protein in HCV-infected HCC. Interest-
ingly, PTEN protein in HCV-infected but HCC-negative
liver (N) also declined to similar extent (Fig. 1d), suggest-
ing that loss of PTEN may be necessary but insufficient to
promote HCC.
The next issue is whether the PTEN produced in
chimeric mouse liver is functional. PTEN is a dual
specificity phosphatase with lipid and protein phosphat-
ase activities [17–19]. Cytoplasmic lipid phosphatase
activity of PTEN is a central negative regulator of
phosphatidylinositol-3-kinase (PI3K) signal cascade for
cell growth and proliferation. Loss of PTEN is associated
with increased phosphorylation of Akt, a proto-oncogene
with key roles in cell survival and cell proliferation in
many types of cancer [15, 16]. We observed increased
phosphor-Akt levels in HCV-infected liver tumor (Fig. 1a,
b and d), consistent with the role of PTEN as a tumor
suppressor.
Nucleus-localized PTEN protein has an essential role
in cell cycle homeostasis and genomic stability [17, 19, 20].
We observed a reduced level of nuclear PTEN that corre-
sponded with increased Cyclin D1 in HCV infection-
associated liver tumors (Fig. 1c). The observed increase in
Cyclin D1 in liver tumors is consistent with enhanced pro-
liferation of HCV-infected hepatocytes [10]. Interestingly,
we observed similar increase in Cyclin D1 of HCV-infected
but HCC-negative liver (Fig. 1c and d), suggesting that
deregulation of the cell cycle is an early event resulting
from PTEN insufficiency of HCV-infected cells.
Induction of c-Myc oncoprotein
c-Myc is a constitutively induced transcription activator
in a broad range of human cancers [21, 22]. We ob-
served increased c-Myc protein levels in HCV-infected
liver tumors compared to the control (Fig. 2a). By
contrast, induction of c-Myc in HCC-negative liver was
modest (Fig. 2d), suggesting that induction of c-Myc
oncoprotein is a relatively late event in the development
of HCV-infection associated HCC.
Down-regulation of DLC-1 tumor suppressor
DLC1 (Deleted in Liver Cancer 1) gene maps to chromo-
some 8 (8p21.3-22), a region that is frequently deleted in
solid tumors. DLC1 encodes GTPase-activating protein
(GAP) that acts as a negative regulator of the Rho family
GTPases [23]. Loss of DLC1 is considered an independent
marker of hepatocellular carcinoma [4, 6]. We observed
the loss of DLC1 protein in HCV-infected liver tumors
and less so in HCV-infected but HCC-negative liver tissue
(Fig. 2b and d).
P21
HCV structural and non-structural proteins have been
shown to interact with and modulate transcriptional regu-
latory activity of p53 tumor suppressor protein [24–26].
Modulation of transcriptional activity of p53 by viral pro-
teins distinguishes HCV from other RNA viruses in its
ability to interfere with the p53 function [13]. Therefore, it
was important to determine if HCV infection of human-




Fig. 1 Tumor suppressor proteins: Liver tissues from control animals (MUP-uPA/SCID/bg mice engrafted with human hepatocytes but not
infected with HCV), HCC-negative mice (engrafted and HCV infected mice that did not develop HCC), and HCC positive mice (engrafted and
HCV infected) were examined by Western blotting with monoclonal antibodies against PTEN, Phospho-Akt or Cyclin D1. Panels (a) and (c) show
representative Western blots of nuclear protein fraction (with Lamin B1 as loading control); and panel (b) is representative Western blot of
corresponding cytoplasmic fraction (with GAPDH as loading control). Liver tissues were homogenized with RIPA buffer, and 30 microgram total
proteins per lane were resolved by SDS-PAGE, and immunoblotted with antibodies as described before [11]. Panel (d) represents quantitative
assessment (fold change) of nuclear or cytoplasmic PTEN (PTEN-N, PTEN-C); cytoplasmic p-Akt or nuclear Cyclin-D1 from the liver tissues. Quantitation
was based on 12 controls, 7 HCC negative and 13 HCC positive liver tissues, analyzed in three independent SDS-PAGE runs. The Western blots were
normalized to the internal “loading” controls (Lamin-B1 for nuclear and GADH for cytoplasmic fractions) (*p < 0.05)
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the modulation of p53 function in HCV-infected chimeric
mice on the basis of p21 expression, a direct target of
p53 transcriptional regulatory function. We observed a
marked decline of p21 protein in HCV-infected liver
tumor (Fig. 2c and d), and less so in HCC-negative mice
(N, Fig. 2d), suggesting that HCC progression is corre-
lated with the loss of function of p53 tumor suppressor.
Inflammatory response
Persistent viral infection is an underlying cause of
inflammation-induced cancer, including HCC. More than
90 % of HCCs arise in the context of hepatic injury and in-
flammation. Inflammation-associated oncogenic response
is mediated by STAT proteins; in particular, activated
STAT3 [27, 28]. To ascertain if HCV infection-associated
HCC in humanized mice mimics the natural inflammatory
response, we assayed activated STAT3 levels in the liver
tumors and in HCC-negative as compared to the unin-
fected control mice. As shown (Fig. 3), there is a marked
induction of activated (phosphorylated) STAT3 in HCV
infection-associated liver tumors as compared to HCV-
infected but HCC-negative liver.
Next, we investigated whether the activation of STAT3
in liver tumors was coordinately regulated with other
inflammatory response proteins, notably interleukin-6
(IL-6) and IL-6R [28–30], in HCV-infected chimeric
mice. As shown in Fig. 3, we observed a parallel increase
in STAT3 and IL-6R in HCV-infected HCC as compared
with control liver, suggesting coordinate regulation of in-
flammatory response molecules in tumor development.
Signal transduction pathways, in particular Wnt sig-
naling, are frequently mutated in liver cancer. Disrup-
tion of Wnt signaling results in β-Catenin stabilization
and translocation to the nucleus where it activates cell
survival and cell proliferation genes [12]. Activation of
β-Catenin in HCC as contrasted with the surrounding
(normal) liver tissue was recently reported from HCV-
infected patients [31]. Considering the significance of
β-Catenin activation and Wnt signaling in human
cancer, we considered it important to investigate the ac-
tivated state of these tumorigenic proteins in HCV
infection-associated HCC in humanized mice. Results
illustrated in Fig. 3a, b show coordinate regulation of in-
flammatory response proteins and deregulation of signal
transduction pathways (activated β-Catenin, IL-6R and
STAT3) in HCV-infected HCC.
MicroRNA markers of HCC
MicroRNAs can function as tumor suppressors or onco-
genes (oncomiRs) [32]. Altered expression levels of miR-
NAs have been reported in a number of human cancers
[8, 32–34]. In this study we sought to identify miRNAs
that would serve as distinguishing markers of HCV
infection-associated HCC.
MicroRNA 141 (miR-141) is induced in HCV-infected
human primary hepatocytes. Importantly, miR-141 dir-
ectly targets DLC1 tumor suppressor protein expression
[10], attesting to its role as bona fide oncomiR. Here we
compared expression levels of miR-141 along with
other known oncomiRs (miR-21 and miR-221) in HCV
infection-induced HCC (Fig. 4). Results suggest that
expression of miR-141 and oncomiRs miR-21 and miR-
221 that target cell cycle inhibitors [34, 35] is coordi-
nately induced in HCV infection-associated HCC.
Tumor suppressor microRNA 26a (miR-26a) is depleted
in liver tumor as compared to the surrounding normal
liver tissues [36]. We then investigated whether the HCV-




Fig. 2 Oncoproteins: Western blots of the control, HCC-negative and liver tumor tissues (as is shown in Fig. 1) were probed with antibodies
against c-Myc, DLC-1 or p21 proteins (panels a, b and b). Panel (d) represents quantitative analysis (based on the loading controls) of liver tissues
from uninfected control, HCC negative and HCC positive mice (as in Fig. 1)
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regulated miR-26a tumor suppressor, resembling the loss
of miR-26a in human HCC. We observed a marked reduc-
tion of miR-26a in liver tumors of human hepatocyte-
engrafted HCV-infected mice compared to controls
(Fig. 4). Our results suggest that induction of oncomiRs
(miR-141, miR-21 and miR-221) and down-regulation of
tumor suppressor miRNA (miR-26a) constitute distin-
guishing markers of HCV infection-associated HCC.
Altered expression levels of miRNAs have also been
reported from liver tumors of heterogeneous origin. To
identify changes in miRNA expression that distinguish
HCV infection-associated HCC, we examined selected
examples of miRNAs that have been reported from stud-
ies of various liver tumors. Increase in miR-181 levels
was reported in AFP-positive tumors and in embryonic
liver cells [37]. Our results by contrast, showed a decline
of miR-181 in HCV infected-HCC (Fig. 5), suggesting
that miR-181 is less reliable indicator of HCV infection-
associated liver tumors.
Contribution of miR-122 in HCV replication has been
studied in a number of cell culture systems and in ani-
mal models; however, its role in HCV infection-related
HCC in humans is less clear [38, 39]. A recent report
[40] suggests that phenotypic effects of miR-122 deple-
tion may be a consequence of its sequestration by HCV
genomic RNA. Our analysis of miR-122 shows an insig-
nificant change in HCV infection-associated HCC of hu-
man hepatocyte-engrafted mice (Fig. 5).
MicroRNA 23a (miR-23a) has been shown to target
genes involved in gluconeogenesis at different stages of
A
B
Fig. 3 Inflammatory response markers: Total proteins from liver tissues of 7 uninfected controls, 8 HCV infected HCC negative and 7 HCV infected
HCC positive mice were analyzed by Western blotting. (Fig. 3a). Representative Western blots of two controls (C), three HCC (T) and three HCC
negative (N) liver are shown. Numbers underneath is relative values normalized to β-Actin loading control. (Fig. 3b): Quantitative assessment of
β-Catenin, STAT-3 and IL-6R (from 7 uninfected control, 8 HCC negative and 7 HCC positive mice) was based on B-Actin internal controls analyzed
by three independent SDS-PAGE runs
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hepatocarcinogenesis in mouse liver as well as in pri-
mary human HCC [41, 42]. In our studies, amplification
of miR-23a appears to be a less specific indicator of
HCV infection-induced HCC of humanized mice. As
shown (in Fig. 5), liver tumors of HCV-infected MUP-
uPA/SCID/bg mice show a relatively modest change in
miR-23a levels.
Our studies suggest that amplification of oncomiRs
(miR-21, miR-221 and miR-141) and the loss of tumor
suppressor miR-26a are specific indicators of HCV
infection-associated HCC. By contrast, altered expression
of miR-181, miR-122 and miR-23a appears to be a less
specific indicator of HCV infection-associated HCC.
Discussion
In this study of a mouse model of HCV infection-
associated liver tumor, we have attempted to identify
tumor suppressor genes and miRNAs whose expression
defines HCV infection-associated HCC. PTEN is a hap-
loinsufficient tumor suppressor gene [43]; single func-
tional allele of PTEN is insufficient to maintain normal
function [44–48]. In particular, insufficiency of nuclear
Fig. 4 Altered MicroRNA expression: Changes in microRNA expression in Controls, HCC negative and Liver Tumor tissues were analyzed by RT-PCR.
Total RNA was prepared by Trizol procedure and equal RNA amounts were analyzed by qRT-PCR. The data represents similar number of Controls,
HCC negative and HCC positive liver tissues (as in Fig. 1), analyzed in triplicates
Fig. 5 HCV non-specific microRNAs: Total RNA from eight HCV infected and four uninfected human hepatocyte engrafted MUP-uPA/SCID/Bg mice
were analyzed by qRT-PCR. Relative values of microRNAs are shown as fold change compared to the uninfected control liver
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PTEN has been shown to result in genomic instability
[49, 50]. HCV utilizes a novel mechanism to induce
PTEN insufficiency, involving viral non-coding RNA di-
rected post-trasncriptional silencing of Transportin-2
that restricts translocation of PTEN protein to the nu-
cleus [9]. The results of PTEN depletion in liver tumors
of HCV-infected humanized mice described here are
consistent with in vitro studies of HCV-infected human
hepatocytes reported earlier [9]. Comparison of PTEN
protein levels of HCV-infected but HCC-negative liver
with the HCV-infected HCC suggest that loss of PTEN
is an early, precancerous event, although PTEN insuffi-
ciency by itself does not promote HCC. Similarly, loss
of DLC-1 tumor suppressor protein appears to be an
early indicator of HCV infection-associated HCC. By
contrast, induction of oncogenic modulators such as
cMyc, miR-21, miR221 and miR-141 appear to be effect-
ive in promoting HCC progression.
Induction of inflammatory effector molecules in HCV
infection-associated HCC described here support the
notion that an inflammatory microenvironment is an es-
sential factor in the development of HCC. Further stud-
ies with the humanized mouse model are needed to
address the issue of whether the oncogenic changes
induced early in HCV infection promote the sustained
inflammatory microenvironment required for tumor
progression [28]. A summary of altered expression levels
of tumorigenic markers during HCC progression is de-
scribed in Table 1.
Induction cMyc oncoprotein is more pronounced
in HCV-infected liver tumors as compared to HCC-
negative liver (Fig. 2a and d), suggesting that the induc-
tion of cMyc oncoprotein is a relatively late event in the
development of hepatocellular carcinoma. By contrast,
down-regulation of tumor suppressor proteins PTEN,
DLC-1 and p21 appears to be initiated early in HCV
infection-associated HCC.
Induction of oncomiRs and inhibition of tumor
suppressor microRNA
MicroRNAs (miRNAs) represent a substantial fraction
of tissue-specific small non-protein coding RNA modula-
tors of gene expression. MicroRNAs can function as gene
silencers by blocking mRNA translation and destabilizing
the target mRNA. Phenotypic consequences of miRNA-
regulated genes evoke essential features of tumor biology,
including modulation of apoptosis, cell proliferation,
signal transduction and stress response. Dysregulated
expression of miRNAs has proven valuable in tumor clas-
sification and prognosis [8, 34, 35]. In this study we have
presented evidence of induction of tumor-promoting
microRNAs, oncomiRs miR-141, miR-21 and miR-221,
and down-regulation of tumor suppressor microRNA,
miR-26a, that represent distinguishing features of HCV
infection-associated HCC. Future studies are needed to
understand how coordinate regulation of miRNA target
genes promote the development of HCV infection-
associated HCC.
Tumor suppressor genes modulate signaling networks
that protect against tumor initiation and progression.
Loss of function of tumor suppressor genes (TSGs) is
generally due to inactivation by deletions, point mutations
or promoter hypermethylation. We present evidence of
down-regulation of tumor suppressor proteins in a hu-
manized mouse model of HCV infection-associated HCC.
These studies represent the first example of functional in-
sufficiency of tumor suppressor proteins induced by HCV
infection. The studies with a humanized mouse model of
HCC should encourage investigation of molecular path-
ways that are modulated by amplification of oncogenes
and the inhibition of tumor suppressor genes.
Abbreviations
Akt: Protein Kinase B, a serine threonine-specific protein kinase that plays a
key role in cell proliferation, transcription and migration; Alb-uPA: Albumin
promoter driving urokinase plasminogen activator transgene; cMyc:
Proto-onco gene that codes for transcription factor named derived from
Avian Myelocytoma viral oncogene); Cyclin D1: Cell cycle kinase co-activator;
DLC-1: Deleted in Liver Cancer1 (DLC1) gene encodes a GTPase activating
protein that functions as a negative regulator of Rho family of GTPases;
Haploinsufficiency: wherein the retained functional copy of a gene
is insufficient to maintain normal function; HBV: Hepatitis B virus;
Table 1 Schematic representation of the relative changes in
oncoproteins or Tumor suppressor proteins, and microRNAs
in HCV-infected HCC negative (N) and liver tumors (T) as
compared with the control liver (derived from the results shown
in Figs. 1, 2, 3, 4 and 5).
Levels
Category Control HCC(Neg) HCC
Tumor Suppressor
PTEN(N) +++ ++ ++/+
PTEN (C ) +++ ++ ++/+
DLC1 +++ ++ +
p21 ++ ++ +
Oncoprotein
p-AKT ++ ++ +++
CyclinD1 + +++ +++
c-myc + + +++
STAT3 + + +++
OncomiR
miR-141 ++ + ++++
miR-221 + + +++
miR-21 + + +++
Tumor Suppressor(miRNA)
miR-26a ++ +++ +
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HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; IL-6R: Interleukin
6 receptor; MUP-uPA/SCID/Bg: Major Urinary Protein promoter driving
urokinase plasminogen activator transgene in severe combined immune
deficient mice, Bg strain; oncomiR: Oncogenic microRNA; p53: (53kda)
tumor suppressor gene; PI3K: Phosphatidylinositol-3-kinase; PTEN: Phosphatase
and tensin homologue deleted on chromosome 10; RT-PCR: Reverse
transcriptase-polymerase Chain Reaction; STAT3: Signal transducer and activator
of transcription protein 3 with inflammation-related oncogenic potential;
Wnt: Oncogenic signaling proteins, described in mouse mammary tumor virus
originally characterized from Drosophila Wingless (g) gene; β-Catenin: Encoded
by CTNB1 gene in humans, a dual function protein regulating cell-cell adhesion
and transcription overexpression of β-Catenin associated with many cancers
including hepatocellular carcinoma.
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